Scholars Central

Conference abstract

Propranolol in angiosarcoma: First major advance in decades

Authors: Shripad Banavali

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Angiosarcomasare rare malignant tumors of vascular origin that represent a therapeutic challenge. In recent times,the combination of metronomic therapies and drug repositioning has been proposed as an effective alternative for cancer patients. We tried to explore such therapies in difficult to treat, metastatic/recurrent, angiosarcoma patients. Methods: In vitro experiments with transformed endothelial cells were used to identify synergistic interactions between betablocker propranolol and various chemotherapeutic drugs. This led to exploration of pilot treatment protocol containing oral propranolol along with metronomic therapies. Treatment was delivered for one year followed by oral maintenance till disease progression. Results: Our data shows that all angiosarcoma tumors express ADRB1 and /or ADRB2 adrenergic receptor genes. Propranolol strongly synergized with micro-tubular-targeting agent vinblastine, but only showed additive or slight antagonism with drugs routinely used for the treatment of angiosarcoma viz. doxorubicin and paclitaxel. Based on this data a combination treatment was designed using oral propranolol / weekly injectable metronomic vinblastineand methotrexate, given for up-to 1 year, followed by oral maintenance with propranolol/ etoposide/ cyclophosphamide. This regimen gave us 100% response rate in the 14 patients treated with median PFS of 10.6 months and OS of 17.8 months. The toxicity was acceptable with 3 patients having grade 3 or 4 toxicity (1 Thrombocytopenia, 1 diarrhea, 1 febrile neutropenia). Conclusion: Our data provides strong rationale for the combination of metronomic chemotherapy and propranolol in angiosarcomawhich warrants additional studies. It also illustrates the potentialof metronomics to generate innovative, yet inexpensive, targeted therapies for both high-income and low/middle income countries.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical & Experimental Pharmacology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical & Experimental Pharmacology
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Shripad Banavali”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels